{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:28:23Z","timestamp":1794454103045,"version":"4.9.1"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Efficacy and safety of albutrepenonacog alfa (rIX\u2010FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real\u2010world data insights are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To describe real\u2010world effectiveness and tolerability of rIX\u2010FP in PwHB in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, non\u2010interventional study conducted across 19 sites in Germany. Patients of any age treated with rIX\u2010FP were enrolled between March 2018 and February 2024. Patients were monitored every 3\u201312 months and followed\u2010up for 3 years or until \u2265100 exposure days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>To our knowledge, this is the largest study of factor replacement therapy in PwHB in Germany to date. Of the patients who completed the study (63\/73), most (80.8%) had moderate or severe haemophilia B. The mean (standard deviation) duration of observation was 30.5 (8.32) months. For any prophylaxis regimen, the median (range) annualised bleeding rate (ABR) was 0.89 (0.0\u20139.6) and annualised spontaneous bleeding rate (AsBR) was 0.08 (0.0\u20135.2). The median ABR was 1.12, 0.68 and 0.13, and the median AsBR was 0.17, 0.00 and 0.06 for those treated with a 7\u2010, 10\u2010 or 14\u2010day regimen, respectively. Investigators rated the overall haemostatic effectiveness as \u2018good\u2019 or \u2018excellent\u2019 in 94% of cases (based on the worst assessment). Overall, 82 adverse events in 34 patients were reported, none were considered related to rIX\u2010FP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multicentre, non\u2010interventional study in Germany demonstrates that rIX\u2010FP prophylaxis is effective and well tolerated in PwHB of all ages in routine clinical practice and reinforces the results of the clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>The study has been registered in the non\u2010interventional studies registry at the Paul Ehrlich Institute (German federal authority for vaccines and biomedicines; study code CSL654_5005; NIS number 410).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70319","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:51:43Z","timestamp":1783421503000},"page":"1429-1443","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2010World Outcomes of Prophylaxis With rIX\u2010FP in Germany: A Prospective, Non\u2010Interventional Study in Haemophilia B"],"prefix":"10.1111","volume":"32","author":[{"given":"Johannes","family":"Oldenburg","sequence":"first","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine University Hospital Bonn, Medical Faculty  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee","family":"Wenning","sequence":"additional","affiliation":[{"name":"SRH Kurpfalzkrankenhaus  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Holzhauer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Charit\u00e9 University Medicine  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"Department of Haemophilia and Haemostasis Vivantes Hospital Friedrichshain  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-9277","authenticated-orcid":false,"given":"Thomas","family":"Linhoff","sequence":"additional","affiliation":[{"name":"CSL Behring  Hattersheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sommerer","sequence":"additional","affiliation":[{"name":"CSL Behring  Hattersheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-7402","authenticated-orcid":false,"given":"Christian","family":"Pfrepper","sequence":"additional","affiliation":[{"name":"Division of Hemostaseology University of Leipzig Medical Center  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-6244","authenticated-orcid":false,"given":"Martin","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Paediatric Thrombosis and Haemostasis Unit, Paediatric Haemophilia Centre Dr. Von Hauner Children's Hospital, LMU Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"all study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"6","key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia","volume":"26","author":"Srivastava A.","year":"2020","journal-title":"Haemophilia"},{"issue":"8","key":"e_1_2_14_3_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The Benefits of Prophylaxis in Patients With Hemophilia B","volume":"11","author":"Castaman G.","year":"2018","journal-title":"Expert Review of Hematology"},{"issue":"12","key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and Pharmacokinetics of a Novel Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX\u2010FP) in Hemophilia B Patients","volume":"120","author":"Santagostino E.","year":"2012","journal-title":"Blood"},{"issue":"4","key":"e_1_2_14_5_1","first-page":"634","article-title":"Genetic Fusion to Albumin Improves the Pharmacokinetic Properties of Factor IX","volume":"102","author":"Metzner H. J.","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"issue":"14","key":"e_1_2_14_6_1","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long\u2010Acting Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX\u2010FP) in Hemophilia B: Results of a Phase 3 Trial","volume":"127","author":"Santagostino E.","year":"2016","journal-title":"Blood"},{"issue":"4","key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1055\/s-0040-1705116","article-title":"Long\u2010Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX\u2010FP) in Previously Treated Pediatric Patients With Hemophilia B: Results From a Phase 3b Extension Study","volume":"120","author":"Kenet G.","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"e_1_2_14_8_1","first-page":"659","article-title":"Long\u2010Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX\u2010FP) in Children. Results of a Phase 3 Trial","volume":"116","author":"Kenet G.","year":"2016","journal-title":"Thrombosis and\u00a0Haemostasis"},{"issue":"5","key":"e_1_2_14_9_1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/jth.14778","article-title":"Long\u2010Term Safety and Efficacy of rIX\u2010FP Prophylaxis With Extended Dosing Intervals up to 21 Days in Adults\/Adolescents With Hemophilia B","volume":"18","author":"Mancuso M. E.","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"e_1_2_14_10_1","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1055\/s-0044-1781466","article-title":"Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX\u2010FP) in Previously Untreated Patients with Hemophilia B","volume":"8","author":"Lemons R.","year":"2024","journal-title":"TH Open"},{"issue":"1","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/03007995.2019.1662675","article-title":"Assessing Bleeding Rates, Related Clinical Impact and Factor Utilization in German Hemophilia B Patients Treated With Extended Half\u2010Life rIX\u2010FP Compared to Prior Drug Therapy","volume":"36","author":"Oldenburg J.","year":"2020","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"e_1_2_14_12_1","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1007\/s12325-020-01300-6","article-title":"Real\u2010World Utilisation and Bleed Rates in Patients With Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX\u2010FP): A Retrospective International Analysis","volume":"37","author":"Hermans C.","year":"2020","journal-title":"Advances in Therapy"},{"issue":"5","key":"e_1_2_14_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102482","article-title":"Real\u2010World Usage and Effectiveness of Recombinant Factor VIII\/Factor IX Fc in Hemophilia A\/B: Final Data From the 24\u2010Month, Prospective, Noninterventional Prevent Study in Germany","volume":"8","author":"Bidlingmaier C.","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"1","key":"e_1_2_14_14_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/hae.14689","article-title":"Ideal Study: A Real\u2010World Assessment of Pattern of Use and Clinical Outcomes With Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX\u2010FP) in Patients With Haemophilia B in Italy","volume":"29","author":"Tagliaferri A.","year":"2023","journal-title":"Haemophilia"},{"issue":"5","key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3390\/jcm13051518","article-title":"Six\u2010Year, Real\u2010World Use of Prophylaxis With Recombinant Factor IX\u2010Albumin Fusion Protein (rIX\u2010FP) in Persons With Hemophilia B: A Single\u2010Center Retrospective\u2010Prospective Study","volume":"13","author":"Coppola A.","year":"2024","journal-title":"Journal of Clinical Medicine"},{"issue":"4","key":"e_1_2_14_16_1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/hae.15074","article-title":"Real\u2010World Experience of rIX\u2010FP Prophylaxis at Dosing Intervals of 14 Days or More in Adult Patients With Haemophilia B in Italy\u2014Results From IDEAL Part B","volume":"30","author":"Coppola A.","year":"2024","journal-title":"Haemophilia"},{"issue":"3","key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/ejh.14357","article-title":"ORPHEE: A Real\u2010World Study on rIX\u2010FP Prophylaxis Use in Adolescent\/Adult Patients With Hemophilia B","volume":"114","author":"Volot F.","year":"2025","journal-title":"European Journal of Haematology"},{"issue":"5","key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/ejh.14168","article-title":"Pattern of Use and Clinical Outcomes With rIX\u2010FP in Pediatric\/Adolescent Patients With Haemophilia B in Italy: Results From IDEAL Real\u2010World Study","volume":"112","author":"Giordano P.","year":"2024","journal-title":"European Journal of Haematology"},{"issue":"1","key":"e_1_2_14_19_1","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2242656","article-title":"Benefits of rIX\u2010FP Prophylaxis in Patients With Haemophilia B: Real\u2010World Evidence From a Spanish Reference Centre","volume":"28","author":"Benitez\u2010Hidalgo O.","year":"2023","journal-title":"Hematology"},{"issue":"5","key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa2514332","article-title":"Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B","volume":"394","author":"Pipe S. W.","year":"2026","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_14_21_1","article-title":"Summary of Product Characteristics","author":"Hemgenix (etranacogene dezaparvovec)","year":"2023","journal-title":"CSL Behring"},{"issue":"6","key":"e_1_2_14_22_1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000911","article-title":"Nonfactor Therapies for Hemophilia","volume":"7","author":"Young G.","year":"2023","journal-title":"Hemasphere"},{"issue":"4","key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/hae.70015","article-title":"Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment","volume":"31","author":"Dargaud Y.","year":"2025","journal-title":"Haemophilia"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70319","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:52:58Z","timestamp":1794451978000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/hae.70319"],"URL":"https:\/\/doi.org\/10.1111\/hae.70319","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2025-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}